We have previously demonstrated that CD4+ T cells reactive against a secreted myeloma protein tumor antigen can mediate protection against tumor development upon challenge with MOPC315 myeloma cells (2, 6, 7, 12). The gene discussed is CD4; the disease is neoplasm.